GBR Connect Series – Interview with Emer Leahy, PsychoGenics
Can you give an overview of how business has evolved for PsychoGenics over the past year? There are two sides...
PsychoGenics’ High Data Security Standards Are Certified by The NIH
PsychoGenics Inc. (PGI), a provider of AI-based phenotypic platforms and preclinical assays for the development of therapeutics for pain, neurodegenerative,...
PsychoGenics Appoints Dr. Stephen Morairty as Vice President, Translational Neuroscience and Jean-Sebastien Valois as Vice President, Engineering and AI Development
PsychoGenics Inc. announced the appointment of Stephen Morairty, Ph.D., as Vice President of Translational Neuroscience and Jean-Sebastien Valois, MSc, as...
PsychoGenics Chief Innovation Officer Honored for Scientific Excellence
PsychoGenics announces that Daniela Brunner Ph.D., Chief Innovation Officer, was named the recipient of Great Minds in STEMTM (GMiS) Scientist of...
PsychoGenics Further Strengthens its Leadership Team, Adding Three Senior Executives
Daniela Brunner, Chief Innovation Officer; Geoffrey Varty, Executive Vice President, Research Operations; and Leslie Street, Vice President, Medicinal Chemistry PsychoGenics Inc....
PsychoGenics Drug Discovery Featured in Nature Biopharma Dealmakers
A phenotypic high-throughput approach to neuropsychiatric drug discovery Using its SmartCube platform along with machine learning algorithms, PsychoGenics has a...
Karuna Therapeutics and PsychoGenics Announce Drug Discovery Collaboration
Multi-year drug discovery collaboration leveraging behavioral and physiological phenotypic screening and machine learning to identify novel neuropsychiatric drug candidates Karuna...